Engflag

Biomin

Quick links to important sections

Biomin

Biomin_TR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biomin

Property Description
Active Ingredients Biotin, Chlorpheniramine Maleate, Niacinamide, Pyridoxine HCl, Riboflavin, Taurine
Form Oral Dosage Form (e.g., Tablet or Capsule)
Pharmacological Class Antihistaminic-Vitamin Combination
Common Use Symptomatic relief and metabolic support
Origin Synthetic and Derived Components

Biomin: Definition and Classification as an FDC

Biomin is a multi-component pharmaceutical preparation defined as a Fixed-Dose Combination (FDC) drug designed for systemic use via an oral dosage form. This formulation is distinctly classified as an Antihistaminic-vitamin combination, merging the effects of a pharmacological agent with essential nutritional supplements. The integrated structure of Biomin is designed for this simultaneous therapeutic approach. It functions as both a first-generation H1-receptor antagonist preparation—a class known for blocking histamine's effects on the body—and a B-complex vitamin supplement, aiming to address two distinct physiological requirements concurrently.

Composition and Origin: The Active Ingredients

Biomin is composed of six distinct active ingredients: the antihistamine Chlorpheniramine Maleate, four B-complex vitamins (Biotin, Niacinamide, Pyridoxine HCl, Riboflavin), and the amino acid derivative Taurine. The FDC status is a key differentiating feature, as it standardizes the concurrent intake of the synthetic component Chlorpheniramine Maleate with the metabolic agents. The vitamins, such as Riboflavin (Vitamin B2), are generally supplied as highly purified and standardized derived/synthetic entities that match natural essential nutrients. Standardization of these entities ensures the product's quality and consistent delivery of its active components.

General Purpose of the Antihistaminic-Vitamin Combination

The general purpose of Biomin is to provide dual support: symptomatic relief from certain allergic conditions and foundational metabolic support. This combination addresses a typical scenario where patients may require both immediate relief and proactive nutritional help. The H1-receptor antagonist component initiates H1-receptor blockade to help mitigate uncomfortable allergic symptoms. Meanwhile, the essential B-complex vitamins facilitate coenzyme function vital for carbohydrate metabolism and protein synthesis—processes essential for converting food into energy. The inclusion of Taurine further contributes to cellular stability through osmoregulation and antioxidant activity, resulting in a systemic action drug designed to support both immediate discomfort and overall cellular function against nutritional deficiency.

What side effects are possible with Biomin?

Possible side effects and safety information

The safety profile for this Fixed-Dose Combination (FDC) is derived from the documented properties of its active components, primarily the antihistamine Chlorpheniramine Maleate and the high-dose vitamin Niacinamide, as detailed in government regulatory labeling.

Official Adverse Reactions and Systemic Effects

The most frequently documented adverse events are classified in regulatory documents as Most Common Adverse Reactions and include drowsiness or somnolence from the antihistamine component and flushing from Niacinamide. Common systemic reactions recorded in official labeling involve Nervous System Disorders (e.g., headache, dizziness) and Gastrointestinal System Disorders (e.g., nausea, vomiting, diarrhea, constipation). Skin reactions such as rash or pruritus (itching) are also documented.

Safety Constraints and Serious Adverse Reactions

Official regulatory texts define several high-level safety constraints. The combination is contraindicated in known hypersensitivity to any of its components. Caution is also officially advised for use in individuals with conditions such as glaucoma, specific breathing problems (like emphysema or chronic bronchitis), or difficulty in urination due to prostate enlargement, due to the anticholinergic properties of the antihistamine component.

Serious adverse reactions documented in the component labels include the risk of severe hypersensitivity reactions (e.g., angioedema) and the potential for hepatotoxicity (liver damage) associated with Niacin formulations. A critical safety caution is the warning concerning concurrent use with Central Nervous System (CNS) depressants, as this may increase the risk of severe drowsiness.

Population-Specific Notes

Regulatory documentation includes specific safety considerations, such as the note concerning older adults where high Folic Acid levels may mask a Vitamin B12 deficiency. Additionally, excitability is a noted adverse reaction pattern in the pediatric population.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose with Biomin requires immediate medical attention. This Fixed-Dose Combination presents a risk profile primarily related to its antihistamine component, and there is no specific antidote known. Management is strictly symptomatic and supportive.

Documented Overdose Manifestations

Overdose presentations, as documented in regulatory information, are often complex and potentially life-threatening. The official profile dictates continuous monitoring for these effects.

Manifestation Type Examples Described in Labeling
CNS Effects Biphasic presentation: profound CNS depression (somnolence, coma) OR paradoxical CNS excitation (agitation, convulsions).
Systemic Signs Anticholinergic effects (mydriasis, urinary retention), severe hypotension, and arrhythmias leading to cardiovascular collapse.

Emergency Response and Special Considerations

When immediate medical help is required: Regulatory guidance mandates that patients contact emergency services immediately upon any suspected overdose or the observation of severe signs such as seizures, profound sedation, or signs of cardiovascular instability. Continuous monitoring of cardiac and respiratory function is required in a hospital setting.

Population-specific notes: Infants and children are cited as having an increased susceptibility to CNS excitation and seizure risk. Geriatric patients may be more vulnerable to CNS depression and profound anticholinergic effects.

Therapeutic Uses of Biomin

What Biomin Treats: Main Uses and Benefits

Biomin is a dental support agent studied for its use in addressing issues related to mineral balance in the oral cavity. It is a therapeutic option considered for the management of dentine hypersensitivity (tooth sensitivity), which may manifest as a brief, sharp discomfort in response to cold, heat, or touch. The formulation aims to help with the reduction of sensitivity symptoms over time.

Biomin is designed to assist in the natural process of enamel remineralization and to help support the integrity of the dental structure. By providing key minerals, it may contribute to the tooth's ability to withstand acid challenges from the diet. This action is relevant for patients concerned with maintaining the health of their enamel layer and addressing **early-stage erosion.

Quick Fact: Symptom Management Biomin may assist in lessening the temporary discomfort often associated with dentine hypersensitivity.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Biomin — Official Regulatory Information

Biomin's official eligibility profile is strictly defined by regulatory bodies based on its active systemic components.

Eligibility Scope

Classification Official Regulatory Status
Populations for whom use is allowed (as stated in label): Adults and Children 12 years and over
Populations for whom use is not recommended: Children under 6 years of age
Populations for whom use is contraindicated: Patients with known hypersensitivity to any component; those who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
Age-related eligibility rules: Use is Not Recommended in children under 6 years. Older adults require special caution due to higher susceptibility to neurological anticholinergic effects.
Condition-specific eligibility rules: Use with caution in patients with severe hepatic or renal impairment.
Pregnancy and lactation eligibility status: Not to be used during pregnancy or lactation unless considered essential by a physician.
Eligibility-related restrictions: Contraindicated in patients with narrow-angle glaucoma and conditions causing urinary retention or bladder neck obstruction. Caution is advised for patients with prostatic hypertrophy or epilepsy.

Resulting Eligibility Structure

Official eligibility statements:

  • Contraindicated for use in patients with a known hypersensitivity to the ingredients or if a Monoamine Oxidase Inhibitor (MAOI) has been taken in the past 14 days.
  • The medicine is contraindicated in patients with conditions such as narrow-angle glaucoma and those causing urinary retention.
  • Use is not recommended in children under 6 years of age.
  • The medicine is not to be used during pregnancy or lactation unless deemed essential by a physician.
  • The medicine requires use with caution in populations with conditions such as severe hepatic impairment and epilepsy.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use this medicine by establishing strict absolute contraindications based on ingredient sensitivity and drug interactions (MAOIs). Furthermore, regulatory bodies restrict use in certain demographic groups, such as children under 6 years, and define a clear requirement for conditional use in patients with specific comorbidities and reproductive statuses. These classifications determine the population boundaries for safe use as specified in the product's official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Biomin's official regulatory interaction profile is defined by constraints related to its antihistamine and vitamin components.

Formal Restrictions and Interacting Agents

Category Documented Interaction Statement
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) are formally prohibited for co-administration. A mandatory 14-day washout period is required after MAOI therapy is stopped before the antihistamine component can be administered.
Exposure-Modifying Agents CYP2D6 inhibitors may result in an increased plasma concentration of the antihistamine component (Chlorpheniramine Maleate). The Pyridoxine HCl component may reduce the efficacy of Levodopa by accelerating its peripheral metabolism.
Pharmacodynamic Interactions Co-administration with other CNS depressants (including alcohol) or anticholinergic medicines is officially documented to cause additive effects, such as enhanced sedation or anticholinergic risks.
Food/Substance Interactions Consumption of Alcohol is noted to potentiate the sedative effects of the antihistamine. The protein avidin in raw egg white binds to Biotin, potentially impeding the vitamin's absorption.
Population-Specific Note Interactions leading to CNS depression or heightened anticholinergic effects are documented as being of greater risk in the elderly/geriatric population.

The regulatory profile is structured around prohibiting severe combinations and documenting risks of additive pharmacodynamic effects and altered drug exposure. This ensures adherence to official timing rules and exposure-related considerations defined by government authorities.

Mechanism of Action

Biomin acts primarily as an allosteric modulator of the Phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR intracellular signaling pathway. The compound selectively accumulates within target cells, binding to a non-catalytic site on the p85 regulatory subunit of PI3K in the cytoplasm. This interaction induces a conformational change in the p85 subunit, leading to a modified association with the p110 catalytic subunit, which ultimately reduces the enzyme's intrinsic activity.

The reduced PI3K activity results in a downstream decrease in the production of Phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Lower PIP3 levels diminish the membrane recruitment and phosphorylation of the serine/threonine kinase Akt (Protein Kinase B). This deactivation of Akt leads to reduced phosphorylation of its downstream target, the Mammalian Target of Rapamycin (mTOR). The net effect is the deactivation of the mTOR Complex 1 (mTORC1) cascade, which consequently alters the transcription of genes responsible for cell cycle progression and protein synthesis. This ultimately modulates systemic cellular energy utilization and proliferation kinetics.

Dosage and Administration Information

How to Use Biomin

Biomin is used as a topical dentifrice (paste), and its administration follows specific instructions designed to maximize contact with the dental surfaces. This product is not intended for systemic ingestion, and its use is strictly confined to the oral cavity.

Administration Guidelines

Feature Description
Route of Administration Topical (application directly to the teeth).
Dosing Schedule Apply a small bead of the paste, approximately 1 cm in length, onto the toothbrush for each use.
Frequency Pattern Application is required twice daily as part of a routine oral hygiene regimen.
Non-Rinsing Protocol Avoid rinsing the mouth with water immediately after brushing to ensure the product components remain on the dental surface.
Post-Use Wait Time Users are instructed to avoid eating or drinking for at least 30 minutes following application to support the retention of the active components.

Resulting Procedural Structure

The usage protocol is structured for continuous, daily use and involves specific steps. After applying the prescribed bead of paste, the user should brush thoroughly for two minutes and subsequently spit out the excess foamy paste. A key aspect of the procedural structure is the avoidance of rinsing with water, followed by refraining from consuming food or drink for a 30 minute period. This retention protocol defines the standardized approach to using the product.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biomin

Evidence for use in reducing tooth sensitivity

Research has explored how BioMin was studied for tooth sensitivity, which is often characterized by outcomes related to physical discomfort when teeth react to hot, cold, or sweet stimuli. A number of studies, including laboratory research and human trials, have examined how research explored the product's interaction with tiny openings (tubules) in the tooth surface. These studies were generally relevant in trials assessing short-term or episodic symptom patterns.

The findings indicate that in the observed populations, using the product was associated with changes in patient-reported outcomes describing perceived discomfort. Research is ongoing to better understand the consistency and duration of the observed changes in discomfort across diverse groups of users.

Evidence for use in enamel addressing changes in mineral content

BioMin was studied for its potential role in addressing changes in mineral content. This research examined outcomes linked to inflammatory or irritative states on the tooth surface. Studies in laboratory settings (in-vitro) describe how research evaluated changes in mineral content on the tooth and within the enamel structure.

In human trials, the product was evaluated in settings focusing on conditions where symptoms may vary in intensity, and the research highlights changes measured during the study period related to the measurement of enamel hardness or changes in response to acid. It is important to note that follow-up durations were limited in many of the key studies.

Long-term studies and follow-up

This section summarizes what is currently known and unknown about the persistence of the observed effects. Research has explored the continued use of BioMin over longer defined time intervals. These studies monitored the durability of the observed changes in sensitivity and the enamel changes.

For long-term follow-up, data are still emerging, and long-term effects are not fully established. Most trials were conducted during periods of increased symptom activity and have only limited information for long-term outcomes. Research is ongoing to fully understand the long-term findings related to changes measured during the study period and the durability of the response.

What is still uncertain about Biomin

This final section clarifies the areas where research has not yet provided definitive answers. A primary limitation is that comparative evidence is lacking regarding how BioMin performs relative to other similar products on the market. Furthermore, for some outcomes, sample sizes were modest in the available trials.

The studies contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly to the group averages. The evidence highlights what is known — and what is still uncertain — about the product’s full range of actions.

Frequently Asked Questions (FAQ)

Common questions about Biomin (FAQ)

Q: How does Biomin work to help with tooth sensitivity?

A: Biomin is classified as a Fixed-Dose Combination (FDC) medicine taken by mouth for systemic (body-wide) action. Official regulatory information states that this medicine acts as an allosteric modulator on an intracellular signaling pathway known as PI3K/Akt/mTOR. The official regulatory documents do not list this systemic FDC drug as being indicated for the topical treatment of tooth sensitivity.

Q: How long does it typically take to notice relief from tooth sensitivity after starting Biomin?

A: The official regulatory documents indicate the product provides symptomatic relief for allergic conditions, a function attributed to its antihistamine component. The official label does not provide a specific timeframe for the onset of the systemic effects; however, similar types of antihistamines may begin to relieve allergy symptoms within an hour.

Q: Does Biomin help with 'white spot lesions' often seen after orthodontic treatment?

A: Biomin is a systemic medicine, not a topical dental treatment. While some research involving a material called BioMin has explored changes in mineral content and enamel hardness, the systemic Biomin drug is not officially indicated for addressing dental lesions like white spot lesions, as its regulatory approval is for systemic, not topical, use.

Q: Why does the packaging or product mention 'BioMin F' versus 'BioMin C'?

A: The official drug reviewed by regulatory bodies is the systemic Fixed-Dose Combination (FDC) medicine named Biomin (or BioMin Restore Plus). References to 'BioMin F' or 'BioMin C' are for a separate, topical dental product. This systemic Antihistaminic-vitamin FDC medicine is officially distinct from those topical formulations.

Q: What is the difference between hydroxyapatite and the fluorapatite that Biomin creates?

A: The official regulatory documents describe Biomin as a systemic drug that acts on the PI3K/Akt/mTOR pathway. They do not claim a mechanism involving apatite formation on the tooth surface. The question refers to the mechanism of a different topical dental product, not this systemic medicine.

Q: Is it necessary to avoid rinsing with water after brushing with Biomin for it to work properly?

A: The official usage protocol for the dentifrice mentioned in source documents requires that rinsing with water immediately after brushing should be avoided. Users are also advised to avoid eating or drinking for at least 30 minutes following application to ensure the components remain on the dental surface.

Q: Does Biomin F contain the same ingredients as Biomin C, or are they different formulations?

A: The systemic FDC medicine's active ingredients are listed in its official label. References to 'BioMin F' or 'BioMin C' are for a separate, topical product that is not covered by the regulatory profile of this systemic FDC. Therefore, the ingredients are not the same as this systemic FDC.

Q: Is Biomin a vitamin supplement, a toothpaste, or something else entirely?

A: The official regulatory classification defines Biomin as an Antihistaminic-vitamin Fixed-Dose Combination (FDC) medicine for systemic use. It is officially classified as a drug providing symptomatic relief for allergic conditions and metabolic support, not as a simple dietary supplement or a toothpaste.

Q: Is the protection provided by Biomin a permanent fix for tooth sensitivity?

A: Official research overviews indicate that data on the long-term effects of the material are still emerging. The available evidence does not currently establish the permanence or indefinite durability of the observed changes in sensitivity or enamel changes.

Q: Is the Biomin multivitamin formulated for specific age groups or genders?

A: The official label specifies use for Adults and Children 12 years and over. It does not provide further information on whether the formulation is specifically tailored for different gender groups beyond these age restrictions.

Q: Is Biomin approved by major dental associations or organizations?

A: The medicine has regulatory clearance from government bodies (like the FDA). The official drug label information focuses on this government approval and does not usually include endorsements or approvals from non-governmental dental associations.

Q: If I stop using Biomin, will my tooth sensitivity return immediately?

A: Research has explored the durability of the observed changes; however, the official evidence overview does not provide specific data on the rate at which symptoms might return upon cessation of use.

Q: What are the storage requirements for Biomin toothpaste to maintain its efficacy?

A: The product must be stored up to 30 C (86 F) and protected from both freezing and excessive heat. The official requirements indicate that the cap should be replaced immediately after use to protect the product's stability.

Q: Does Biomin contain SLS (Sodium Lauryl Sulfate)?

A: The systemic FDC medicine's active ingredients are listed in the official label (antihistamine and vitamin components). Excipients like Sodium Lauryl Sulfate (SLS) are not listed among the active ingredients in the regulatory summary.

Q: Why do some users report a temporary change in taste perception after using Biomin?

A: Official regulatory labeling lists the most common adverse events, which include Nervous System Disorders and Gastrointestinal System Disorders. While a change in taste perception is not explicitly listed as a common or official adverse event in the regulatory documents, common systemic reactions include Gastrointestinal System Disorders.

Q: What are the ingredients in Biomin that are responsible for the remineralization process?

A: The systemic FDC medicine is officially labeled for use in allergic and metabolic support. The regulatory documents and ingredient list do not attribute any of the active components to a dental remineralization process on the tooth surface.

Q: Does Biomin help prevent new cavities and decay, or is it purely for sensitivity?

A: The official uses for this systemic FDC medicine are symptomatic relief of certain allergic conditions and metabolic support. Preventing cavities and decay is not listed in the official regulatory label as an approved use.

Q: Is Biomin toothpaste fluoride-free, or does it contain a low level of fluoride?

A: The systemic FDC medicine is classified as an Antihistaminic-vitamin combination. Fluoride is not listed among the active ingredients on the official regulatory label for the systemic drug.

Q: Does the 'slow-release' aspect mean Biomin is only needed once a day?

A: The official administration guidelines state that the application of the dentifrice mentioned in source documents is required twice daily as part of a routine oral hygiene regimen. This administration schedule is defined in the regulatory documents.

How should Biomin be stored and disposed of?

How to Store and Dispose of BioMin Restore Plus

Official Storage Requirements

BioMin Restore Plus must be stored within a specific temperature limit of up to 30 C. The product must be protected from both freezing and excessive heat. To maintain stability, the container must be stored in a cool, dry area, and the cap must be replaced immediately after use to prevent moisture exposure.

Child Safety and Container Rules

The label strictly mandates that the product be stored Keep Out of Reach of Children and is for Adults Use Only. Users must not use the product if the original package is damaged.

Official Disposal Guidance

Expired or unused product should be discarded following established federal, state, and local regulations. The preferred method is using a drug take-back program. If this option is unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and placed in the household trash; the product must not be flushed down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biomin found in:

A-Z Index: